Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.
With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.
Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.
Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.
Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.
Takeda Pharmaceutical Company (TSE:4502/NYSE:TAK) announced the dosing of the first participant in its Phase 1/2 study of Novavax's COVID-19 vaccine candidate (TAK-019) in Japan. This follows the completion of enrollment in a similar study for Moderna's TAK-919 vaccine. Takeda aims to manufacture over 250 million doses of TAK-019 and import 50 million doses of TAK-919 for distribution in Japan. Results from both studies are anticipated in 2021, with an intention to distribute the vaccines pending regulatory approvals.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 SOLSTICE trial for TAK-620 (maribavir), aimed at treating refractory cytomegalovirus (CMV) infections in transplant recipients. The trial met its primary endpoint, showing 55.7% of patients cleared CMV viremia by Study Week 8 compared to 23.9% with conventional therapies (p<0.001). Maribavir also demonstrated lower rates of treatment-related toxicities, such as neutropenia and acute kidney injury. The trial's promising findings may redefine CMV treatment in transplant patients, although regulatory approvals remain uncertain.
Takeda reported Q3 FY2020 financial results, highlighting a 3.6% revenue decline to JPY 2,427.5 billion, impacted by foreign exchange and divestitures. However, underlying revenue grew by 1.1%, driven by strong performances from ENTYVIO and TAKHZYRO. Operating profit surged by 120.7% to JPY 358.7 billion, while net profit rose by 320.8% to JPY 178.9 billion. The company confirmed its FY2020 guidance, anticipating growth acceleration. Takeda also achieved significant cost savings and divestitures, exceeding its $10 billion target. Positive R&D developments promise future growth potential.
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) announced the presentation of 14 abstracts from its Hematology portfolio at the Virtual EAHAD 2021 Congress. Key findings from the seven-year AHEAD study revealed that prophylactic antihemophilic factor (rAHF) significantly reduced annualized bleeding rates in severe hemophilia A patients compared to on-demand treatment. Additional research highlighted the effectiveness of switching to alternative treatments like rurioctocog alfa pegol and emicizumab. The studies underscore the importance of real-world evidence in hemophilia management, showcasing Takeda's commitment to innovation and patient care.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has completed the sale of TachoSil® Fibrin Sealant Patch to Corza Health for €350 million. This transaction allows Corza to acquire the necessary assets and licenses for TachoSil®, while Takeda retains the manufacturing facility in Linz, Austria, and will exclusively produce TachoSil® under a long-term supply agreement. The proceeds from this sale will aid in reducing Takeda's debt as part of a strategy to achieve a target of 2x net debt/adjusted EBITDA by FY 2023.
Takeda Pharmaceutical Company has finalized the sale of a portfolio of select products in Latin America to Hypera S.A. for $825 million USD. This divestment, initially announced in March 2020, includes over-the-counter and prescription products. Approximately 300 commercial employees will transition to Hypera, while Takeda will continue to manufacture these products. Proceeds from the sale aim to reduce debt, targeting a net debt/adjusted EBITDA ratio of 2x by 2023. This sale contributes to Takeda's broader strategy, having exceeded its $10 billion non-core asset divestiture target in 2020.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has revealed promising new data from a Phase 1/2 trial of mobocertinib (TAK-788) for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC). The results indicate a 35% confirmed objective response rate and a median duration of response of 17.5 months in platinum-pretreated patients. Despite a manageable safety profile, mobocertinib is not yet FDA-approved. Takeda plans to submit findings to regulatory agencies globally and will host an investor briefing on January 29.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced new findings from the Phase 1/2 trial of mobocertinib (TAK-788) for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC). The late-breaking results presented at the IASLC 2020 WCLC indicate a confirmed objective response rate (ORR) of 35% and a median duration of response (DoR) of 17.5 months in platinum-pretreated patients. Takeda plans to submit these data to regulatory authorities globally. Mobocertinib is not yet approved for this indication.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has achieved carbon neutrality in its value chain for fiscal year 2019. This milestone was reached through energy conservation, green energy procurement, and investment in verified carbon offsets. Takeda aims to reduce operational emissions by 40% by 2025 and achieve carbon neutrality by 2040. The company supports over 30 renewable energy projects across 12 countries, addressing 15 out of 17 UN Sustainable Development Goals. Recognized for its climate leadership, Takeda has been named on CDP’s 'A List' and Corporate Knights Global 100 Most Sustainable Corporations.
Takeda Pharmaceutical Company Limited (NYSE:TAK) has received recognition in the 2021 Access to Medicine Index, ranking sixth overall among 20 pharmaceutical companies. The company excelled in Governance of Access, R&D capacity, and health system strengthening. Notably, Takeda ranked first in Governance of Access and led the industry for R&D capacity building. Its initiatives focus on affordable access, assessed access strategies, and local healthcare programs, such as the Blueprint for Innovative Healthcare Access in Kenya and Rwanda, aimed at enhancing medicine accessibility.
FAQ
What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What are Takeda Pharmaceutical's core therapeutic areas?
Where is Takeda Pharmaceutical headquartered?
What recent collaborations has Takeda Pharmaceutical entered into?
How diversified is Takeda's revenue geographically?
What was Takeda's revenue in fiscal 2023?
Who can benefit from Takeda's new drug NBI-1065845?
What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?
How long has Takeda been in the pharmaceutical industry?
In how many countries does Takeda operate?
How does Takeda contribute to the field of major depressive disorder treatment?
